Search results
Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
Simply Wall St. via Yahoo Finance UK· 5 hours agoWhile Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shareholders have enjoyed a good week with stock...
What’s Next For Alnylam Stock After A 60% Rise In A Week?
Forbes· 1 day agoAlnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference...
Alnylam's heart disease drug meets main goal in late-stage study
Reuters· 5 days ago, opens new tab said on Monday that its drug vutrisiran met the main goal in a late-stage study testing it as a treatment for a type of heart disease. Treatment with the drug showed a statistically ...
Alnylam Pharma Shares Surge 30% After Rare Heart Disease Drug Succeeds
Forbes· 5 days agoShares of Alnylam Pharmaceuticals rose by over 32%, the company’s largest single-day gain in nearly...
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Zacks via Yahoo Finance UK· 2 days agoIt was a busy week for the biotech sector with quite a few important pipeline and regulatory...
Alnylam Shares Soar After Drug Meets Goal in Heart Disease Trial
Bloomberg· 5 days agoHave a confidential tip for our reporters? Alnylam Pharmaceuticals Inc. shares soared after its drug...
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?
Zacks via Yahoo Finance UK· 5 days agoAlnylam (ALNY) saw its shares surge in the last session with trading volume being higher than...
Company News for Jun 25, 2024
Zacks via Yahoo Finance UK· 4 days ago(UPS) for more than $1 billion. Shares of Eli Lilly and Co. (LLY) rose 0.7% following news that the company’s weight loss drug tirzepatide reduced the...
Top Three US Stocks Estimated Below Intrinsic Value In June 2024
Simply Wall St. via Yahoo Finance UK· 4 days agoAs of June 2024, the U.S. stock market presents a mixed landscape, with the Dow Jones advancing...
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024
Associated Press Finance via Yahoo Finance UK· 5 days agoResMed Inc., down $23.63 to $182.20. The maker of sleep apnea devices slipped after Eli Lilly reported encouraging results from a study on a drug for the condition. Alnylam